KeyZell, a Spanish biotechnology company in the development phase of 
digital cancer treatments and tools, has just opened a private financing round 
which expects to achieve 5 million euros to boost its projects and consolidate 
itself as one of the biotech start-ups with the greatest international 
projection.

    KeyZell launches this new round of private investment to conduct a human 
clinical trial with one of its innovative cancer treatments, based on Dr. Nabil 
Hajji's research on cellular apoptosis induced by cell receptor blockage, as 
well as to improve its precision medicine Artificial Intelligence system that 
aims to be the future of cancer medicine, thanks to an algorithm that proposes 
the most appropriate personalized treatment for each patient depending on the 
unique characteristics of each person and type of cancer.

    KeyZell has already generated great interest from both national private 
investors and North American investment funds and has successfully closed a 
preliminary round of 450,000 euros, 50% above expectations. Among its investors 
are professional brokers as well as Spanish and Mexican businessmen.

    "We created KeyZell with the objective of developing new cancer solutions 
and tools that can help both medical professionals and patients in their fight 
against this disease. This financing round will allow us to achieve our 
ambitious objective," says Jose del Corral, company CEO.

    The company is committed to blockchain technology, implementing 
improvements on its AI-based tool and thus reinforcing this through clinical 
trials. Keyzell plans to finance the clinical trial in Australia while in 
negotiations with a strategic partner to carry out another trial in Mexico. In 
addition, working on the structures to carry out regulatory processes in 
Europe, United States, United Kingdom, Thailand, South Africa, Morocco and 
Canada.

    Keyzell has the pleasure of having Dr. Nabil Hajji among its founders who 
has led the research with collaborators from University of Seville and Harvard 
University, where they have discovered a new treatment which for the first 
time, after more than twenty years without advances in glioblastoma research, 
has succeeded in eliminating the most aggressive brain cancer, glioblastoma.

    Media Contact:
    Inés Martínez
    imartinez@tinkle.es 
    +34 661 750 597
 

    Source: KeyZell